바이오테크 보도자료
-
- Takeda’s EXKIVITY™ (mobocertinib) Approved by U.S. FDA as the First Oral Therapy Specifically Designed for Patients with EGFR Exon20 Insertion+ NSCLC
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) has approved EXKIVITY (mobocertinib) for the treatment of adult patients with locally advanced or metastatic non-...
- 2021년 09월 17일
-
- Waters BioAccord System with ACQUITY Premier Brings Greater Simplicity, Accuracy and Reproducibility to Multi-Attribute Monitoring of Biopharmaceuticals
- Waters Corporation (NYSE:WAT) today introduced the Waters™ BioAccord™ System with ACQUITY™ Premier, a combination of the Waters BioAccord System and the breakthrough ACQUITY Premier UPLC™ with MaxPeak™ High Performance Surface (HPS) technology. Th...
- 2021년 09월 17일
-
- Virpax® Pharmaceuticals Announces Pricing of $40 Million Public Offering of Common Stock
- Virpax® Pharmaceuticals Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing pharmaceutical products for pain management, today announced the pricing of an underwritten public offering of 6,670,000 shares of its com...
- 2021년 09월 16일
-
- ACQUITY Premier 장착 Waters BioAccord 시스템, 바이오의약품의 다중특성 모니터링(MAM)에 있어 간편성과 재현성 향상 극대화 구현
- Waters Corporation(NYSE:WAT)이 Waters BioAccord 시스템과 MaxPeak™ HPS(High Performance Surface) 기술이 적용된 획기적인 ACQUITY Premier UPLC™ 결합 시스템인 ACQUITY™ Premier 장착 Waters™ BioAccord™ 시스템을 출시했다. 통합된 고분해능 LC-MS 시스템은 ...
- 2021년 09월 16일
-
- ZOLL Medical Corporation Signs Definitive Agreement to Acquire Itamar Medical
- ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, and Itamar™ Medical Ltd. (Nasdaq and TASE: ITMR), a medical device and digital health company focused on the integration of sleep a...
- 2021년 09월 14일
-
- Merck to Present Latest Highlights From Oncology Portfolio at WCLC and ESMO 2021
- Merck, a leading science and technology company, today announced research from Company-sponsored, investigator-sponsored, and collaborative studies — including two oral and two mini-oral presentations — at this year’s World Conference on Lung Canc...
- 2021년 09월 13일
-
- Galderma to Present New Data From Leading Aesthetics Portfolio and Launch* RESTYLANE® EYELIGHT™ at AMWC 2021
- Galderma today announced new results from its robust pipeline and portfolio of dermal fillers and toxin injections. Eleven e-posters from Galderma-sponsored and investigator-initiated trials have been accepted at the upcoming Aesthetic & Anti-Agin...
- 2021년 09월 10일
-
- Taulia Announces H1 FY2022 Results With Supply Chain Finance Revenue Growing 42%
- Taulia, the leading fintech provider of working capital solutions today announces a strong first half of the fiscal year, with revenue from its Supply Chain Finance solution growing 42% year over year. During the period, Taulia also added 11 major...
- 2021년 09월 10일
-
- Roswell Park Comprehensive Cancer Center Licenses Invivoscribe’s LymphoTrack Software for Plug and Play Pipeline Use
- Invivoscribe, Inc., a technology-driven international company focused on precision diagnostics with best-in-class products and services that optimize patient care and accelerate drug approvals worldwide, today announced licensing of key software a...
- 2021년 09월 03일
-
- Takeda Provides Update on Phase 3 PANTHER (Pevonedistat-3001) Trial
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the Phase 3 PANTHER (Pevonedistat-3001) study did not achieve pre-defined statistical significance for the primary endpoint of event-free survival (EFS). The...
- 2021년 09월 02일
전시회
